GW Pharmaceuticals Limited: Business Overview, Financials & Competitive Analysis
GW Pharmaceuticals Limited scores 5/10 on the AskCyborg Cyborg Score (Mixed). Established cannabinoid pharma leader facing margin pressure but supported by strong market valuation and Jazz Pharmaceuticals parent backing. Net income of -58.13 M USD as of July 13, 2026, representing a 544.51% decline from -9.02 M USD in the prior year, signals operational challenges. However, market cap of $6.91B.
What is GW Pharmaceuticals Limited's industry? GW Pharmaceuticals Limited (gwpharm.co.uk) operates in Pharmaceuticals. AskCyborg classifies GW Pharmaceuticals Limited under Pharmaceuticals in its company registry.
GW Pharmaceuticals is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is now a subsidiary of Jazz Pharmaceuticals, th...
Cyborg Score thesis
Established cannabinoid pharma leader facing margin pressure but supported by strong market valuation and Jazz Pharmaceuticals...
Read the full analyst-debate transcript →Get the Latest GW Pharmaceuticals Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGW Pharmaceuticals Limited Overview
Pro stress-test →GW Pharmaceuticals is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is now a subsidiary of Jazz Pharmaceuticals, though its shares continue to trade on NASDAQ under the GWPH ticker. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia.
Strategic Profile
Pro stress-test →The company's lead product, Sativex, is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. GW Pharmaceuticals focuses on developing cannabinoid-based prescription medicines, with Epidiolex (Epidyolex in Europe) and Nabiximols (Sativex) as key products. As a Jazz Pharmaceuticals subsidiary, the company maintains its specialized cannabis-medicine focus within a larger diversified pharmaceutical portfolio.
Competitive Landscape
Pro stress-test →GW Pharmaceuticals competes in the prescription cannabinoid pharmaceuticals segment. Direct competitors include clinical-stage cannabis medicine developers and established pharmaceutical companies expanding into cannabinoid therapeutics. The company's competitive advantage stems from early-mover status, established regulatory approvals (particularly Epidiolex for seizures in Europe and US), and proven manufacturing capabilities. However, the segment remains nascent with emerging competitors and evolving regulatory frameworks.
Industry Context
GW Pharmaceuticals Limited operates in Pharmaceuticals.
Key facts
Founded: 1998 · Headquarters: Cambridge, United Kingdom · Employees: 1,161 (2020 baseline) · Revenue: Estimated $527M+ (based on 2020 baseline of $527M); current 2026 revenue not publicly detailed in available sources · Market cap: $6.91B (May 2026)